Journal Mobile Options
Table of Contents
Vol. 1, No. 1, 2006
Issue release date: March 2006
Section title: Review Article · Übersichtsarbeit
Breast Care 2006;1:22-25
(DOI:10.1159/000091116)

Screening in Women with Increased Breast Cancer Risk

Artmann A. · Hellerhoff K. · Heywang-Köbrunner S.H.
Abteilung für Bildgebende und Interventionelle Mammadiagnostik, Klinikum rechts der Isar, TU München, Germany
email Corresponding Author

Abstract

About 10% of all breast cancer cases occur on a hereditary basis. BRCA1/2 (breast cancer oncogenes) account for about 50% of all hereditary breast cancer cases. The remaining cases of suspected inherited origin given by family histories might be associated with other known or currently unknown genes. Deleterious mutations in the BRCA1 or BRCA2 genes are associated with an increased life-time risk of breast and ovarian cancer. BRCA1/2 carriers are more likely in to develop breast cancer at a young age compared with the general population. For women at high breast cancer risk with a mean age under 40 years at diagnosis reported sensitivities of mammography and ultrasound are low, ranging around 30-40%. Using magnetic resonance imaging (MRI) as a complementary imaging tool the sensitivity may increase to 90%. However, the specificity of MRI appears to be generally lower than that of mammography and ultrasound. The data differ depending on patient selection and study design. However, all studies indicate that contrast enhanced magnetic resonance imaging may be the most promising method. Further investigations are still needed to minimize the false-postive rate and to investigate the efficacy of MRI as an integral screening modalitiy in the surveillance of women with increased breast cancer susceptibility.

Abstract of Review Article · Übersichtsarbeit

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

About 10% of all breast cancer cases occur on a hereditary basis. BRCA1/2 (breast cancer oncogenes) account for about 50% of all hereditary breast cancer cases. The remaining cases of suspected inherited origin given by family histories might be associated with other known or currently unknown genes. Deleterious mutations in the BRCA1 or BRCA2 genes are associated with an increased life-time risk of breast and ovarian cancer. BRCA1/2 carriers are more likely in to develop breast cancer at a young age compared with the general population. For women at high breast cancer risk with a mean age under 40 years at diagnosis reported sensitivities of mammography and ultrasound are low, ranging around 30-40%. Using magnetic resonance imaging (MRI) as a complementary imaging tool the sensitivity may increase to 90%. However, the specificity of MRI appears to be generally lower than that of mammography and ultrasound. The data differ depending on patient selection and study design. However, all studies indicate that contrast enhanced magnetic resonance imaging may be the most promising method. Further investigations are still needed to minimize the false-postive rate and to investigate the efficacy of MRI as an integral screening modalitiy in the surveillance of women with increased breast cancer susceptibility.


Article / Publication Details

First-Page Preview
Abstract of Review Article · Übersichtsarbeit

Published online: 2/2/2006
Issue release date: March 2006

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1661-3791 (Print)
eISSN: 1661-3805 (Online)

For additional information: http://www.karger.com/BRC


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.